FENC:NASDAQFennec Pharmaceuticals Inc. Analysis
Data as of 2026-09-27 - not real-time
$10.61
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Fennec Pharmaceuticals Inc. trades at $10.61, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. It has lost 12.1% over the past 30 days. Relative strength is 42.2 — neutral — and the MACD signal is bearish. The recent range runs from support at $10.14 up to resistance at $12.79.
The shares look undervalued, trading on 11.2 times earnings below a sector average of 30.5. Sell-side targets cluster 66.6% above the current quote. Revenue is growing at 85.2% on a -5.5% profit margin.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 41.7%, a beta of 1.38 and a maximum drawdown of 41.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Timeframes disagree: the short-term read is buy while the long-term read is hold, conviction 3 out of 10.
The shares look undervalued, trading on 11.2 times earnings below a sector average of 30.5. Sell-side targets cluster 66.6% above the current quote. Revenue is growing at 85.2% on a -5.5% profit margin.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 41.7%, a beta of 1.38 and a maximum drawdown of 41.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Timeframes disagree: the short-term read is buy while the long-term read is hold, conviction 3 out of 10.
Top Market Events
Fennec Pharmaceuticals is back in focus after analysts lifted their fair value estimate from US$15.Fennec Pharmaceuticals To Report Second Quarter 2026 Financial Results On August 11, 2026.RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 GLOBE NEWSWIRE -- Fennec Pharmaceuticals Inc. NASDAQ: FENC; TSX: FRX , a...
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 8.86
- MACD momentum is negative
Medium Term
1–3 yearsPositive
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 11.2 versus sector average of 30.5
- Trading above the 200-day average of 8.86
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 11.2 versus sector average of 30.5
- Negative profit margin of -5.5%
- Analyst targets imply +66.6% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth85.20%
Profit Margin-5.49%
P/E Ratio11.2
ROE-18.58%
ROA-1.17%
P/B Ratio8.8
Op. Cash Flow$-2040000
Free Cash Flow$1.1M
Industry P/E30.5
Technical Analysis
TrendBullish
RSI42.2
Support$10.14
Resistance$12.79
MA 20$11.36
MA 50$11.10
MA 200$8.86
MACDBearish
VolumeDecreasing
Fear & Greed Index94.88
Valuation
Fair Value$2.17
Target Price$17.67
Upside/Downside66.59%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.38
Volatility41.72%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.